What is the Risk of Transmitting HIV?


© Shutterstock

December 01, 2015 18:16 EDT

There are new effective strategies to reduce the risk of HIV infection.

Charlie Sheen’s recent announcement that he has HIV has raised concerns about whether he may have transmitted the infection to other people.

While we obviously don’t know his specific medical details (and really, it’s none of our business), HIV treatment is effective at reducing transmission. This is known as the “treatment as prevention” strategy.

There have been many advances in HIV care since Rock Hudson was diagnosed in the 1980s. At this time, the prognosis of AIDS was similar to patients with advanced cancer. Since the mid-1990s, combinations of antivirals have markedly improved the survival of people living with HIV. Modern combinations are simple to take (as few as one tablet, once a day) and associated with much fewer side effects than older drugs.

The life expectancies of people living with HIV are now comparable to the general population, both in the developed and developing world.

Antiviral drugs work by interfering with the replication of HIV. This results in a drop in the viral load—the concentration of virus detectable in blood. This doesn’t mean, however, that the virus is eradicated. HIV can hide in sanctuary sites in the body (known as “latency”) and will quickly become detectable if the antivirals are stopped. In many people taking treatment, the concentration of virus is often undetectable, but this doesn’t exclude the possibility of very small amounts of circulating virus that are below the limit of the tests that detect them.

One in 200

In the era before treatment, it was estimated that the risk of acquiring HIV was around one in 200 sexual encounters, which varied by the type of act and other factors.

There are now two new effective strategies to reduce this risk and prevent HIV infection: treating the person with HIV to suppress their viral load; and giving antivirals to the uninfected partner (“prophylaxis”) to stop them becoming infected.

A trial of 1,763 couples where one partner was HIV positive and the other was HIV negative recorded only one transmission in the group on antiviral treatment compared to 27 who were not on treatment. Two other ongoing studies have reported no transmissions in more than 1,300 couples where the HIV-positive partner was successfully treated with antivirals.

It should be noted that the participants of these trials were given the usual advice to prevent HIV transmission in addition to antiviral treatment, including the use of condoms. The initial trial primarily included heterosexual couples, but the subsequent studies have extended the evidence to gay men.

For the uninfected partner, post-exposure prophylaxis (taking antivirals like a “morning after pill”) or pre-exposure prophylaxis (taking antivirals continuously like the oral contraceptive) are also effective options.

In those taking preventive antivirals, the protection against HIV infection appears to be near complete. But as with the oral contraceptive, antivirals only work if they are taken.

Treatment as Prevention

The evidence suggests both strategies are highly effective at preventing HIV infection. However, antivirals do have some potential side effects. And in many countries they are not yet approved for prophylaxis. They also do not protect against other sexually transmitted infections (such as syphilis or gonorrhoea) and need to be combined with other risk-reduction strategies.

Both “treatment as prevention” and pre-exposure prophylaxis rely on the individual knowing his or her HIV status. This reinforces the importance of diagnosing HIV, so that treatment can be offered both for the benefit of the person with HIV, as well as for their uninfected partners.

Like the prevention of pregnancy, there are many potential options to prevent HIV and these should be carefully considered with the person’s treating doctor. But “treatment as prevention” and pre-exposure prophylaxis are clearly major advances in our goal to eliminate HIV transmission.

*[This article was originally published by The Conversation.]

The views expressed in this article are the author’s own and do not necessarily reflect Fair Observer’s editorial policy. 

Photo Credit: Africa Studio /

Fair Observer - World News, Politics, Economics, Business and CultureWe bring you perspectives from around the world. Help us to inform and educate. Your donation is tax-deductible. Join over 400 people to become a donor or you could choose to be a sponsor.

Support Fair Observer

We rely on your support for our independence, diversity and quality.

For more than 10 years, Fair Observer has been free, fair and independent. No billionaire owns us, no advertisers control us. We are a reader-supported nonprofit. Unlike many other publications, we keep our content free for readers regardless of where they live or whether they can afford to pay. We have no paywalls and no ads.

In the post-truth era of fake news, echo chambers and filter bubbles, we publish a plurality of perspectives from around the world. Anyone can publish with us, but everyone goes through a rigorous editorial process. So, you get fact-checked, well-reasoned content instead of noise.

We publish 2,500+ voices from 90+ countries. We also conduct education and training programs on subjects ranging from digital media and journalism to writing and critical thinking. This doesn’t come cheap. Servers, editors, trainers and web developers cost money.
Please consider supporting us on a regular basis as a recurring donor or a sustaining member.

Will you support FO’s journalism?

We rely on your support for our independence, diversity and quality.

Donation Cycle

Donation Amount

The IRS recognizes Fair Observer as a section 501(c)(3) registered public charity (EIN: 46-4070943), enabling you to claim a tax deduction.

Make Sense of the World

Unique Insights from 2,500+ Contributors in 90+ Countries

Support Fair Observer

Support Fair Observer by becoming a sustaining member

Become a Member